Jeremy Tomlinson

• AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome.

  O'Reilly MW. et al, (2017), J Clin Endocrinol Metab

• Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia.

  Jones CM. et al, (2017), J Clin Endocrinol Metab, 102, 1797 - 1806

• 11β-HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice.

  Doig CL. et al, (2017), Endocrinology, 158, 1964 - 1976

• Acute Hypercortisolemia Exerts Depot-Specific Effects on Abdominal and Femoral Adipose Tissue Function.

  Manolopoulos KN. et al, (2017), J Clin Endocrinol Metab, 102, 1091 - 1101

• Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond.

  Konstantakou P. et al, (2017), J Matern Fetal Neonatal Med, 30, 284 - 293

• Baseline morning cortisol level as a predictor of pituitary-adrenal reserve: a comparison across three assays.

  Sbardella E. et al, (2017), Clin Endocrinol (Oxf), 86, 177 - 184

• Elevated hepatic and adipose hepcidin expression in patients with advanced NAFLD fibrosis

  Ryan JD. et al, (2017), JOURNAL OF HEPATOLOGY, 66, S431 - S431

• Cortisol metabolism, postnatal depression and weight changes in the first 12 months postpartum.

  Rogers SL. et al, (2016), Clin Endocrinol (Oxf), 85, 881 - 890

• Optimizing human hepatocyte models for metabolic phenotype and function: effects of treatment with dimethyl sulfoxide (DMSO).

  Nikolaou N. et al, (2016), Physiol Rep, 4

• Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alström syndrome.

  Gathercole LL. et al, (2016), Liver Int, 36, 1704 - 1712

• Changes in adipose tissue gene expression profile and fat mass are associated with deteriorating glucose tolerance

  Woods CP. et al, (2016), IRISH JOURNAL OF MEDICAL SCIENCE, 185, 372 - 372

• Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.

  Larner DP. et al, (2016), Endocrinology, 157, 3493 - 3504

• Non-alcoholic fatty liver disease and diabetes.

  Hazlehurst JM. et al, (2016), Metabolism, 65, 1096 - 1108

• Response to the Letter: "Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man".

  Hazlehurst JM. and Tomlinson JW., (2016), The Journal of clinical endocrinology and metabolism, 101, L48 - L49

• Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

  Armstrong MJ. et al, (2016), Lancet, 387, 679 - 690

• Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.

  Armstrong MJ. et al, (2016), J Hepatol, 64, 399 - 408

• Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.

  Hazlehurst JM. et al, (2016), J Clin Endocrinol Metab, 101, 103 - 113

• Glucocorticoids and non-alcoholic fatty liver disease.

  Woods CP. et al, (2015), J Steroid Biochem Mol Biol, 154, 94 - 103

• Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol.

  Woods CP. et al, (2015), Eur J Endocrinol, 173, 633 - 642

• 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes.

  Nasiri M. et al, (2015), Endocrinology, 156, 2863 - 2871

• Gender-Specific Differences in Skeletal Muscle 11β-HSD1 Expression Across Healthy Aging.

  Hassan-Smith ZK. et al, (2015), J Clin Endocrinol Metab, 100, 2673 - 2681

• LIRAGLUTIDE IS EFFECTIVE IN THE HISTOLOGICAL CLEARANCE OF NON-ALCOHOLIC STEATOHEPATITIS IN A MULTICENTRE, DOUBLE-BLINDED, RANDOMISED, PLACEBO-CONTROLLED PHASE II TRIAL

  Armstrong MJ. et al, (2015), GUT, 64, A9 - A9

• Early occurrence of new-onset diabetes after transplantation is related to type of liver graft and warm ischaemic injury.

  Hartog H. et al, (2015), Liver Int, 35, 1739 - 1747

• Differential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis.

  Nanus DE. et al, (2015), Arthritis Res Ther, 17

• Differential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis

  Nanus DE. et al, (2015), Arthritis research & therapy, 17

• Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT).

  Woods CP. et al, (2015), J Clin Endocrinol Metab, 100, 1434 - 1444

• LIRAGLUTIDE IS EFFECTIVE IN THE HISTOLOGICAL CLEARANCE OF NON-ALCOHOLIC STEATOHEPATITIS IN A MULTICENTRE, DOUBLE-BLINDED, RANDOMISED, PLACEBO-CONTROLLED PHASE II TRIAL

  Armstrong MJ. et al, (2015), JOURNAL OF HEPATOLOGY, 62, S187 - S187

• Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis.

  Weston CJ. et al, (2015), J Clin Invest, 125, 501 - 520

• The Dehydrogenase Hypothesis.

  Woods C. and Tomlinson JW., (2015), Adv Exp Med Biol, 872, 353 - 380

• Differential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray study.

  Shahmanesh M. et al, (2015), PLoS One, 10

• Central hypoadrenalism.

  Crowley RK. et al, (2014), J Clin Endocrinol Metab, 99, 4027 - 4036

• Longitudinal changes in glucocorticoid metabolism are associated with later development of adverse metabolic phenotype.

  Crowley RK. et al, (2014), Eur J Endocrinol, 171, 433 - 442

• Insulin upregulates AKR1C3 expression in female adipose tissue: in vivo and in vitro evidence for adipose androgen generation in polycystic ovary syndrome (PCOS)

  O'Reilly MW. et al, (2014), IRISH JOURNAL OF MEDICAL SCIENCE, 183, S445 - S445

• Understanding androgen action in adipose tissue.

  O'Reilly MW. et al, (2014), J Steroid Biochem Mol Biol, 143, 277 - 284

• Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis.

  Armstrong MJ. et al, (2014), Diabetes Obes Metab, 16, 651 - 660

• 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess.

  Morgan SA. et al, (2014), Proc Natl Acad Sci U S A, 111, E2482 - E2491

• The Systemic 'Spill-over' of sFRP2 in Obesity

  Bujalska I. et al, (2014), ENDOCRINE REVIEWS, 35

• Systolic Blood Pressure Increases with Time in Obese Patients and Is Predicted By Adipose Expression of the Mineralocorticoid Receptor Gene

  Crowley RK. et al, (2014), ENDOCRINE REVIEWS, 35

• Systolic Blood Pressure Increases with Time in Obese Patients and Is Predicted By Adipose Expression of the Mineralocorticoid Receptor Gene

  Crowley RK. et al, (2014), ENDOCRINE REVIEWS, 35

• Longitudinal Changes in Glucocorticoid Metabolism Are Associated with Later Development of Adverse Metabolic Phenotype

  Crowley RK. et al, (2014), ENDOCRINE REVIEWS, 35

• Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers.

  Thomas JM. et al, (2014), Psychopharmacology (Berl), 231, 2449 - 2459

• Androgen Receptor Activation Stimulates Hepatic Lipid Accumulation in Human Hepatocytes

  Nikolaos N. et al, (2014), ENDOCRINE REVIEWS, 35

• Aging Determines the Expression of Key Regulatory Gene Clusters in Human Adipose Tissue

  Manolopoulos KN. et al, (2014), ENDOCRINE REVIEWS, 35

• Adrenal Insufficiency Due to Prescribed Glucocorticoids Is Associated with Adverse Outcome: An Analysis of 3666 ACTH Stimulation Tests

  Chapman MJ. et al, (2014), ENDOCRINE REVIEWS, 35

• Accelerated Progression to Steatohepatitis in 11(a)over-cap-Hydroxysteroid Dehydrogenase Type 1 Knockout Mice Fed a Steatogenic Diet

  Lamer DP. et al, (2014), ENDOCRINE REVIEWS, 35

• 11 beta-HSD1 Is the Major Regulator of the Tissue-Specific Effects of Circulating Glucocorticoid Excess

  Morgan SA. et al, (2014), ENDOCRINE REVIEWS, 35

• 5 Alpha-Reductase Is a Regulator of Glucocorticoid Action and Metabolic Phenotype in Human Liver

  Nasiri M. et al, (2014), ENDOCRINE REVIEWS, 35

• Diminished 11β-hydroxysteroid dehydrogenase type 2 activity is associated with decreased weight and weight gain across the first year of life.

  Rogers SL. et al, (2014), J Clin Endocrinol Metab, 99, E821 - E831

• Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.

  Dowman JK. et al, (2014), Am J Pathol, 184, 1550 - 1561

• HEPATITIS B AND C VIRUS PROMOTE CROSSTALK BETWEEN HYPOXIA AND GLUCOCORTICOID SIGNALLING PATHWAYS TO RE-PROGRAMME HEPATOCYTE METABOLISM AND TO EVADE HOST INTERFERONS

  Wilson GK. et al, (2014), JOURNAL OF HEPATOLOGY, 60, S129 - S130

• Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.

  O'Reilly MW. et al, (2014), J Clin Endocrinol Metab, 99, 1027 - 1036

• Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management.

  Armstrong MJ. et al, (2014), QJM, 107, 33 - 41

• Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis

  Armstrong MJ. et al, (2014), Diabetes, Obesity and Metabolism, 16, 651 - 660

• Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice.

  Dowman JK. et al, (2013), Endocrinology, 154, 4536 - 4547

• Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial.

  Armstrong MJ. et al, (2013), BMJ Open, 3

• Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake.

  McNelis JC. et al, (2013), Am J Physiol Endocrinol Metab, 305, E1134 - E1144

• Androgenemic Phenotype Predicts Metabolic Disease and Androgen Burden in Polycystic Ovary Syndrome

  O'Reilly MW. et al, (2013), IRISH JOURNAL OF MEDICAL SCIENCE, 182, S410 - S410

• Subcutaneous adipose tissue insulin resistance and lipolysis in patients with nonalcoholic steatohepatitis

  Armstrong MJ. et al, (2013), HEPATOLOGY, 58, 474A - 474A

• Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial

  Armstrong MJ. et al, (2013), HEPATOLOGY, 58, 476A - 476A

• Non-alcoholic fatty liver disease in common endocrine disorders.

  Hazlehurst JM. and Tomlinson JW., (2013), Eur J Endocrinol, 169, R27 - R37

• 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects.

  Gathercole LL. et al, (2013), Endocr Rev, 34, 525 - 555

• Regulation of lipid metabolism by glucocorticoids and 11β-HSD1 in skeletal muscle.

  Morgan SA. et al, (2013), Endocrinology, 154, 2374 - 2384

• Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue in vivo.

  Hazlehurst JM. et al, (2013), J Clin Endocrinol Metab, 98, 1631 - 1640

• Safety and efficacy of liraglutide in patients with type 2 diabetes with elevated liver enzymes: individual patient data meta-analysis of the LEAD programme

  Armstrong MJ. et al, (2013), LANCET, 381, 20 - 20

• A comparative quality assessment of evidence-based clinical guidelines in endocrinology.

  Hazlehurst JM. et al, (2013), Clin Endocrinol (Oxf), 78, 183 - 190

• Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

  Armstrong MJ. et al, (2013), Aliment Pharmacol Ther, 37, 234 - 242

• Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program

  Armstrong MJ. et al, (2013), Alimentary Pharmacology and Therapeutics, 37, 234 - 242

• Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.

  Chortis V. et al, (2013), J Clin Endocrinol Metab, 98, 161 - 171

• Hormonal regulation of lipogenesis.

  Gathercole LL. et al, (2013), Vitam Horm, 91, 1 - 27

• Effects of interventions in pregnancy on maternal weight and obstetric outcomesMeta-analysis of randomised evidence

  Thangaratinam S. et al, (2012), Obstetrical and Gynecological Survey, 67, 603 - 604

• Urinary Glucocorticoid Metabolite Excretion is Associated with Insulin Resistance Independent of BMI in Patients with Polycystic Ovary Syndrome

  O'Reilly MW. et al, (2012), IRISH JOURNAL OF MEDICAL SCIENCE, 181, S343 - S343

• Genotype-phenotype correlation in Bardet-Biedl Syndrome

  Forsythe E. et al, (2012), JOURNAL OF MEDICAL GENETICS, 49, S71 - S71

• Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1.

  Lavery GG. et al, (2012), Endocrinology, 153, 3236 - 3248

• Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence.

  Thangaratinam S. et al, (2012), BMJ, 344

• Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis.

  Newsome PN. et al, (2012), Gut, 61, 484 - 500

• 5-ALPHA-REDUCTASE-1 KNOCKOUT PROTECTS AGAINST HEPATOCARCINOGENESIS IN A MURINE MODEL OF NASH

  Dowman JK. et al, (2012), JOURNAL OF HEPATOLOGY, 56, S488 - S489

• The diagnosis of non-alcoholic fatty liver disease: Authors' reply

  Dowman JK. et al, (2012), Alimentary Pharmacology and Therapeutics, 35, 205 - 206

• Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.

  McGee KC. et al, (2012), Antivir Ther, 17, 495 - 507

• A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease.

  Ahmed A. et al, (2012), PLoS One, 7

• VASCULAR ADHESION PROTEIN-1 PROMOTES INCREASES IN LIVER INFILTRATING CD4+T CELLS AND NKT CELLS AND INDUCTION OF FIBROGENESIS IN STEATOHEPATITIS

  Claridge LC. et al, (2011), GUT, 60, A40 - A40

• 5 alpha-REDUCTASE-1 KNOCKOUT PROMOTES STEATOSIS BUT PROTECTS AGAINST HEPATOCARCINOGENESIS IN A MURINE MODEL OF NAFLD

  Dowman JK. et al, (2011), GUT, 60, A39 - +

• Current therapeutic strategies in non-alcoholic fatty liver disease.

  Dowman JK. et al, (2011), Diabetes Obes Metab, 13, 692 - 702

• Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

  Dowman JK. et al, (2011), Aliment Pharmacol Ther, 33, 525 - 540

• Short- and long-term glucocorticoid treatment enhances insulin signalling in human subcutaneous adipose tissue.

  Gathercole LL. et al, (2011), Nutr Diabetes, 1

• Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue.

  Gathercole LL. et al, (2011), PLoS One, 6

• Cerebrospinal fluid corticosteroid levels and cortisol metabolism in patients with idiopathic intracranial hypertension: a link between 11beta-HSD1 and intracranial pressure regulation?

  Sinclair AJ. et al, (2010), J Clin Endocrinol Metab, 95, 5348 - 5356

• Special issue on Steroids in Obesity and Diabetes.

  Tomlinson JW. and Tchernof A., (2010), J Steroid Biochem Mol Biol, 122, 1 - 2

• 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.

  Morgan SA. and Tomlinson JW., (2010), Expert Opin Investig Drugs, 19, 1067 - 1076

• Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study.

  Sinclair AJ. et al, (2010), BMJ, 341

• Prospective Changes in Glucocorticoid Metabolism Predict Alterations in Metabolic Phenotype.

  Gray J. et al, (2010), ENDOCRINE REVIEWS, 31

• Mortality in patients with pituitary disease.

  Sherlock M. et al, (2010), Endocr Rev, 31, 301 - 342

• Impact of Glucocorticoids upon Lipogenesis and beta-Oxidation in Skeletal Muscle.

  Morgan SA. et al, (2010), ENDOCRINE REVIEWS, 31

• Glucocorticoid and Insulin Regulation of Lipogenesis in Human Adipose Tissue.

  Gathercole LL. et al, (2010), ENDOCRINE REVIEWS, 31

• Cortisol Metabolism and Hepatic Expression of 11 beta-Hydroxysteroid Dehydrogenase Type 1 in Patients with Non Alcoholic Fatty Liver Disease.

  Ahmed A. et al, (2010), ENDOCRINE REVIEWS, 31

• Complications of HIV Disease or Treatment

  Shahmanesh M. et al, (2010), HIV MEDICINE, 11, 10 - 10

• Glucocorticoid and insulin regulation of lipogenesis in human adipose tissue

  Gathercole LL. et al, (2010), ENDOCRINE JOURNAL, 57, S408 - S408

• Pathogenesis of non-alcoholic fatty liver disease.

  Dowman JK. et al, (2010), QJM, 103, 71 - 83

• The role of 11beta-hydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy.

  Tomlinson JW. et al, (2010), J Clin Endocrinol Metab, 95, 398 - 406

• 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle.

  Morgan SA. et al, (2009), Diabetes, 58, 2506 - 2515

• Nonclassic lipoid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency.

  Metherell LA. et al, (2009), J Clin Endocrinol Metab, 94, 3865 - 3871

• Effects of glucocorticoids on fat mass and the therapeutic potential of targeting IIβ-hydroxysteroid dehydrogenase type I in obesity

  Tomlinson JW., (2009), Future Lipidology, 4, 439 - 447

• Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.

  Vassiliadi DA. et al, (2009), J Clin Endocrinol Metab, 94, 3558 - 3566

• Orlistat for overweight subjects with nonalcoholic steatohepatitis.

  Dowman JK. et al, (2009), Hepatology, 50

• Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance?

  Ball AK. et al, (2009), Clin Endocrinol (Oxf), 70, 863 - 869

• Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?

  Stewart PM. and Tomlinson JW., (2009), Diabetes, 58, 14 - 15

• Changes in the adipocyte (lipid and glucose metabolism) gene expression following 18-24 months treatment with ZDV or TDF-containing ART; and adipocyte mitochondrial gene expression

  Gathercole LL. et al, (2009), ANTIVIRAL THERAPY, 14, A9 - A10

• Adipocyte mitochondrial gene expression following 18-24 months treatment with zidovidine or tenofovir-containing antiretroviral therapy

  McGee KC. et al, (2009), ANTIVIRAL THERAPY, 14, A10 - A10

• Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.

  Boothby M. et al, (2009), Antivir Ther, 14, 1089 - 1100

• Regulation - The real threat to clinical research

  Stewart P. et al, (2008), BMJ, 337, 1085 - 1087

• 11beta-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets.

  Swali A. et al, (2008), Diabetologia, 51, 2003 - 2011

• Regulation--the real threat to clinical research.

  Stewart PM. et al, (2008), BMJ, 337

• Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency.

  Lavery GG. et al, (2008), J Clin Endocrinol Metab, 93, 3827 - 3832

• Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.

  Tomlinson JW. et al, (2008), Diabetes, 57, 2652 - 2660

• Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids.

  Holme J. et al, (2008), Eur Respir J, 32, 1047 - 1052

• Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss.

  Tomlinson JW. et al, (2008), Diabetes, 57, 1536 - 1543

• Lack of hexose-6-phosphate dehydrogenase impairs lipid mobilization from mouse adipose tissue.

  Bujalska IJ. et al, (2008), Endocrinology, 149, 2584 - 2591

• A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis.

  Bujalska IJ. et al, (2008), J Endocrinol, 197, 297 - 307

• NMR based metabolomic analysis of CSF in neurological diseases: A diagnostic tool?

  Sinclair AJ. et al, (2008), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 79, 354 - 355

• Cytokine profiles in idiopathic intracranial hypertension

  Ball AK. et al, (2008), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 79, 355 - 355

• HIV infection significantly reduces lipoprotein lipase which remains low after 6 months of antiretroviral therapy

  Boothby M. et al, (2008), ANTIVIRAL THERAPY, 13, A57 - A57

• Modulation of glucocorticoid action and the treatment of type-2 diabetes.

  Tomlinson JW. and Stewart PM., (2007), Best Pract Res Clin Endocrinol Metab, 21, 607 - 619

• Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue.

  Gathercole LL. et al, (2007), J Clin Endocrinol Metab, 92, 4332 - 4339

• 11beta-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function.

  Walker EA. et al, (2007), J Biol Chem, 282, 27030 - 27036

• Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.

  Wiegand S. et al, (2007), Eur J Endocrinol, 157, 319 - 324

• Corticosteroids, 11beta-hydroxysteroid dehydrogenase isozymes and the rabbit choroid plexus.

  Sinclair AJ. et al, (2007), J Neuroendocrinol, 19, 614 - 620

• Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.

  Tomlinson JW. et al, (2007), J Clin Endocrinol Metab, 92, 857 - 864

• Characterisation of 11beta-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat.

  Bujalska IJ. et al, (2007), J Endocrinol, 192, 279 - 288

• Cerebrospinal fluid and a novel cortisol generating system in the choroid plexus

  Sinclair AJ. et al, (2007), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 78, 216 - 216

• 11 beta-hydroxysteroid dehydrogenase type 1 in obese children

  Wiegand S. et al, (2007), EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 115, S32 - S32

• The effect of antiretroviral therapy on genes involved with glucose and lipid metabolism

  Boothby M. et al, (2007), ANTIVIRAL THERAPY, 12, L12 - L13

• The effect of antiretroviral therapy on genes involved with mitochondrial function

  Boothby M. et al, (2007), ANTIVIRAL THERAPY, 12, L23 - L23

• Expression profiling of 11beta-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes.

  Bujalska IJ. et al, (2006), J Mol Endocrinol, 37, 327 - 340

• Depot-specific prostaglandin synthesis in human adipose tissue: a novel possible mechanism of adipogenesis.

  Quinkler M. et al, (2006), Gene, 380, 137 - 143

• The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic-pituitary-adrenal axis.

  Agha A. et al, (2006), J Clin Endocrinol Metab, 91, 43 - 47

• Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.

  Tomlinson JW. and Stewart PM., (2005), Nat Clin Pract Endocrinol Metab, 1, 92 - 99

• 11β-Hydroxysteroid dehydrogenase type 1 as a therapeutic target in the metabolic syndrome

  Tomlinson JW. and Stewart PM., (2005), Drug Discovery Today: Therapeutic Strategies, 2, 93 - 96

• Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1.

  Bujalska IJ. et al, (2005), J Mol Endocrinol, 34, 675 - 684

• 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.

  Tomlinson JW., (2005), Minerva Endocrinol, 30, 37 - 46

• Androgen generation in adipose tissue in women with simple obesity--a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5.

  Quinkler M. et al, (2004), J Endocrinol, 183, 331 - 342

• 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.

  Tomlinson JW. et al, (2004), Endocr Rev, 25, 831 - 866

• 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.

  Valsamakis G. et al, (2004), J Clin Endocrinol Metab, 89, 4755 - 4761

• Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue.

  Tomlinson JW. et al, (2004), J Clin Endocrinol Metab, 89, 2711 - 2716

• Cerebrospinal fluid production - A role for 11 beta-hydroxysteroid dehydrogenase type 1?

  Rauz S. et al, (2004), INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 45, U498 - U498

• A rabbit model for evaluating corticosteroid metabolism in ocular and orbital tissues

  Walker EA. et al, (2004), INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 45, U498 - U498

• "Cushing's disease of the omentum"--fact or fiction?

  Tomlinson JW. and Stewart PM., (2004), J Endocrinol Invest, 27, 171 - 174

• Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency.

  Draper N. et al, (2003), Nat Genet, 34, 434 - 439

• Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity.

  Tomlinson JW. et al, (2003), J Clin Endocrinol Metab, 88, 2113 - 2118

• Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity.

  Tomlinson JW. et al, (2002), J Clin Endocrinol Metab, 87, 5630 - 5635

• The functional consequences of 11beta-hydroxysteroid dehydrogenase expression in adipose tissue.

  Tomlinson JW. and Stewart PM., (2002), Horm Metab Res, 34, 746 - 751

• 11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol.

  Bujalska IJ. et al, (2002), Endocr Res, 28, 449 - 461

• Cortisol, 11 beta-hydroxysteroid dehydrogenase type 1 and central obesity.

  Stewart PM. and Tomlinson JW., (2002), Trends Endocrinol Metab, 13, 94 - 96

• Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion.

  Tomlinson JW. et al, (2002), J Clin Endocrinol Metab, 87, 57 - 62

• Premature mortality and hypopituitarism.

  Erfurth EM. et al, (2001), Lancet, 357

• Premature mortality and hypopituitarism - Authors' reply

  Stewart PM. et al, (2001), LANCET, 357, 1973 - 1974

• Regulation of Expression of 11β-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue: Tissue-Specific Induction by Cytokines.

  Tomlinson JW. et al, (2001), Endocrinology, 142, 1982 - 1989

• Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines.

  Tomlinson JW. et al, (2001), Endocrinology, 142, 1982 - 1989

• Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase.

  Tomlinson JW. and Stewart PM., (2001), Best Pract Res Clin Endocrinol Metab, 15, 61 - 78

• Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group.

  Tomlinson JW. et al, (2001), Lancet, 357, 425 - 431

• Association between premature mortality and hypopituitarism

  Tomlinson JW. et al, (2001), Lancet, 357, 425 - 431

• Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.

  Stewart PM. et al, (2001), Horm Res, 56 Suppl 1, 1 - 6

• The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis.

  Tomlinson JW. et al, (2000), Endocr Res, 26, 711 - 722

• SFRP2 Is Associated with Increased Adiposity and VEGF Expression.

  Crowley RK. et al, PLoS One, 11

Selected Publications

• Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.

  Hazlehurst JM. et al, (2016), J Clin Endocrinol Metab, 101, 103 - 113

• Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.

  Armstrong MJ. et al, (2016), J Hepatol, 64, 399 - 408

• 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes.

  Nasiri M. et al, (2015), Endocrinology, 156, 2863 - 2871

Recent Publications

• AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome.

  O'Reilly MW. et al, (2017), J Clin Endocrinol Metab

• Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia.

  Jones CM. et al, (2017), J Clin Endocrinol Metab, 102, 1797 - 1806

• 11β-HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice.

  Doig CL. et al, (2017), Endocrinology, 158, 1964 - 1976

• Acute Hypercortisolemia Exerts Depot-Specific Effects on Abdominal and Femoral Adipose Tissue Function.

  Manolopoulos KN. et al, (2017), J Clin Endocrinol Metab, 102, 1091 - 1101

• Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond.

  Konstantakou P. et al, (2017), J Matern Fetal Neonatal Med, 30, 284 - 293